


1/26



PATENT
Customer No. 22,852
Attorney Docket No. 09487.0003-00000

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:)
)
John DEVANE)
)
Application No.: 10/798,421)
)
Filed: March 12, 2004)
)
For: TREATMENT OF INTESTINAL)
)
CONDITIONS WITH N-2,3,3-)
)
TETRAMETHYLBICYCLO[2.2.1])
)
HEPTAN-2-AMINE)

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

INFORMATION DISCLOSURE STATEMENT UNDER 37 C.F.R. § 1.97(b)

Pursuant to 37 C.F.R. §§ 1.56 and 1.97(b), Applicant brings to the attention of the Examiner the documents listed on the attached PTO 1449 form. This Information Disclosure Statement is being filed within three months of the filing date of the above-referenced application and before the mailing date of a first Office Action on the merits for the above-referenced application.

Copies of the listed documents, including any copending patent applications, are attached.

Applicant respectfully requests that the Examiner consider the listed documents and indicate that they were considered by making appropriate notations on the attached form.


This submission does not represent that a search has been made or that no better art exists and does not constitute an admission that each or all of the listed documents are material or constitute "prior art." If the Examiner applies any of the documents as prior art against any claim in the application and Applicant determines that the cited documents do not constitute "prior art" under United States law, Applicant reserves the right to present to the office the relevant facts and law regarding the appropriate status of such documents.

Applicant further reserves the right to take appropriate action to establish the patentability of the disclosed invention over the listed documents, should one or more of the documents be applied against the claims of the present application.

If there is any fee due in connection with the filing of this Statement, please charge the fee to our Deposit Account No. 06-0916.


Respectfully submitted,

FINNEGAN, HENDERSON, FARABOW,
GARRETT & DUNNER, L.L.P.


Chantal Morgan D'Apruzzo
Reg. No. 48,825 for

Dated: May 5, 2004

By: _____
William L. Strauss
Reg. No. 47,114



INFORMATION DISCLOSURE CITATION

Atty. Docket No. 187.0003-00000	Appln. No. 10/798,421
Applicant John DEVANE	
Filing Date March 12, 2004	Group: unassigned

U.S. PATENT DOCUMENTS

Examiner Initial*	Document Number	Issue Date	Name	Class	Sub Class	Filing Date If Appropriate
	Publication No. US 2001/0014678 A1	Published 08/16/2001	Cary	514	252.15	02/20/2001
	Publication No. US 2002/0004065 A1	Published 01/10/2002	Kanios	424	449	01/19/2001
	Publication No. US 2002/0016370 A1	Published 02/07/2002	Shytle, <i>et al.</i>	514	661	06/15/2001
	Publication No. US 2002/0016371 A1	Published 02/07/2002	Shytle, <i>et al.</i>	514	661	06/15/2001
	Publication No. US 2002/0103109 A1	Published 08/01/2002	Glick, <i>et al.</i>	514	1	01/18/2002
	6,121,289	09/19/2000	Houdi	514	315	10/09/1998
	6,034,079	03/07/2000	Sanberg, <i>et al.</i>	514	225.8	11/23/1998

FOREIGN PATENT DOCUMENTS

Document Number	Publication Date	Country	Class	Sub Class	Translation Yes or No
WO 03/090731	11/6/2003	PCT	A61K	31/05	

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

	Kachur, <i>et al.</i> , "Pharmacological effects of 1,2,3,5,6,10b-hexahydropyrido[2,3g]indolizine, a bridged-nicotine analog," <i>Life Sci.</i> , 38(4): 323-330 (1986).
	Nordberg, <i>et al.</i> , "Uptake and regional distribution of (+)-(R)- and (-)-(S)-N-[methyl- ¹¹ C]-nicotine in the brains of Rhesus monkey. An attempt to study nicotinic receptors in vivo," <i>J. Neural Transm. Park Dis. Dement. Sect.</i> , 1(3): 195-205 (1989)
	Papke, <i>et al.</i> , "Analysis of mecamylamine stereoisomers on human nicotinic receptor subtypes," <i>J. Pharmacol. Exp. Ther.</i> , 297(2): 646-656 (2001)
	Sloan, <i>et al.</i> , "Nature of nicotine binding to rat brain P ₂ fraction," <i>Pharmacol. Biochem. Behav.</i> , 20(6):899-909 (1984)



OMB No. 0651-0011

INFORMATION DISCLOSURE CITATION

Atty. Docket No.	094600003-00000	Appln. No.	10/798,421
Applicant	John DEVANE		
Filing Date	March 12, 2004	Group:	unassigned

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)	
	Sloan, <i>et al.</i> , "The comparative binding characteristics of nicotinic ligands and their pharmacology," <i>Pharmacol. Biochem. Behav.</i> , 30(1):255-267 (1988)
	Targacept press release entitled "Targacept and Dr. Falk Pharma Successfully Complete Phase I Studies of First in Class Drug for Ulcerative Colitis," Winston-Salem, NC, October 1, 2002
	Thompson, <i>et al.</i> , "Functional bowel disorders and functional abdominal pain," <i>Gut</i> . 45 (Suppl. II): 1143-1147.
	Young, <i>et al.</i> "Mecamylamine: new therapeutic uses and toxicity/risk profile," <i>Clinical Therapeutics</i> 23(4):532-565 (2001)
	Zevin, <i>et al.</i> , "Nicotine-mecamylamine interactions," <i>Clin. Pharmacol. Ther.</i> , 68(1):58-66 (2000).

Examiner	Date Considered
*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	
Form PTO 1449	Patent and Trademark Office - U.S. Department of Commerce

403757_1.DOC